Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Abbisko Therapeutics and AstraZeneca Launch Strategic Collaboration on Novel Targeted-Immuno Combination Therapy for EGFR-Mutated NSCLC

Fineline Cube Jul 2, 2026
Company Deals

RaysightMed Secures Nearly RMB 100 Million in Strategic Financing Led by State-Owned Capital – Accelerates Cardiovascular Diagnostics Scale-Up and AI Surgical Robotics Development

Fineline Cube Jul 1, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Fineline Cube Jul 2, 2026
Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Fineline Cube Jul 2, 2026
Company Deals

Acotec Scientific Holdings and Boston Scientific Group plc Sign MOU to Broaden Collaboration

Fineline Cube Jun 19, 2023

China-based Acotec Scientific Holdings Ltd (HKG: 6669) has announced a memorandum of understanding (MoU) with...

Company Drug

Aosaikang Pharmaceutical’s ASKB589 Shows Promising Results in Solid Tumor Treatment Study

Fineline Cube Jun 19, 2023

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has revealed the latest results from a Phase...

Company Deals

Jiangsu Hengrui Medicine Cancels Licensing Agreement with Mabworks Citing Market Changes

Fineline Cube Jun 19, 2023

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced its decision to cancel a...

Company Drug

Roche’s Evrysdi Receives NMPA Approval for Wider SMA Patient Age Range

Fineline Cube Jun 19, 2023

Swiss pharmaceutical giant Roche (SWX: ROG) has announced that its blockbuster nervous system drug Evrysdi...

Company Drug

MicuRx Pharmaceuticals’ MRX-4/Contezolid Combo Receives Clinical Trial Approvals for Diabetic Foot Infection

Fineline Cube Jun 19, 2023

Sino-US firm MicuRx Pharmaceuticals Inc. (SHA: 688373) has announced receiving clinical trial approvals for its...

Company Deals

AstraZeneca Enters Three-Year Collaboration with Cholesgen for Metabolic Disease Therapies

Fineline Cube Jun 19, 2023

UK-based pharmaceutical giant AstraZeneca (AZ, NASDAQ: AZN) has signed a three-year collaboration agreement with China-based...

Company Drug

BeiGene to Showcase Brukinsa Data at ICML, Highlighting Efficacy in Relapsed Follicular Lymphoma

Fineline Cube Jun 16, 2023

China-based biopharmaceutical company BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has announced that it will...

Company Drug

Fosun Pharma Initiates Phase II Study of HLX26 and Serplulimab Combo for Metastatic CRC

Fineline Cube Jun 16, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the initiation of...

Company Drug

CStone’s Sugemalimab Shows Promising Survival Rates in Stage IV NSCLC Treatment

Fineline Cube Jun 16, 2023

China-based CStone Pharmaceuticals (HKG: 2616) has announced that the prestigious journal Nature Cancer has published...

Company Drug

Takeda and HutchMed’s Elunate Study Results Published in The Lancet

Fineline Cube Jun 16, 2023

Takeda (TYO: 4502) and HutchMed (China) Ltd (HKG: 0013, NASDAQ: HCM) have announced that the...

Company Deals

Gates Foundation Renews Partnership with Beijing and Tsinghua to Boost Infectious Disease Research

Fineline Cube Jun 16, 2023

The Bill & Melinda Gates Foundation has announced the renewal of its collaboration with the...

Company Deals

Grifols AS Plans to Sell Stake in Shanghai RAAS Blood Products Co., Ltd for Up to $1.5 Billion

Fineline Cube Jun 16, 2023

Spain-based Grifols AS (NASDAQ: GRFS), a leading global player in the blood products industry, has...

Company Deals Digital

Sperogenix Therapeutics and LUCA Healthcare Join Forces to Advance Digital Therapy for Myasthenia Gravis

Fineline Cube Jun 16, 2023

China-based rare disease specialist Sperogenix Therapeutics Limited has entered into a partnership with compatriot firm...

Company Drug

Jiangxi Jemincare’s JYB1907 Receives NMPA Approval for Clinical Study in Solid Tumors

Fineline Cube Jun 16, 2023

China-based Jiangxi Jemincare Group has announced that it has received approval from the China National...

Company Medical Device

NMPA Approves Suzhou MicroPort Joint Medical Technology’s Zirconium Niobium Alloy Femoral Head for Hip Replacement

Fineline Cube Jun 16, 2023

The National Medical Products Administration (NMPA) has granted marketing approval to Suzhou MicroPort Joint Medical...

Company Drug

Cytocraft Biotech’s SDT-T002 Cell Therapy Approved for Advanced Liver Cancer by NMPA

Fineline Cube Jun 16, 2023

China-based Cytocraft Biotech Development has announced that its cell therapy, SDT-T002, has obtained clinical trial...

Company Deals

Laekna Raises £791 Million in Hong Kong IPO for Pipeline Expansion

Fineline Cube Jun 16, 2023

Sino-US Laekna (HKG: 2105) has successfully raised £791 million through an initial public offering (IPO)...

Company Drug

Grand Pharmaceutical’s STC3141 Achieves Clinical Endpoint in Sepsis Study

Fineline Cube Jun 16, 2023

China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that the Phase Ib REFINE study...

Company

Everest Medicines Appoints Dr. Mike Berry as Chief Technology Officer to Drive Innovation

Fineline Cube Jun 16, 2023

China-based Everest Medicines (HKG: 1952) has announced the appointment of Dr. Mike Berry as Chief...

Company Legal / IP

AbbVie Inc. Files Lawsuit Against BeiGene Over BTK Inhibitor Brukinsa

Fineline Cube Jun 15, 2023

US-based AbbVie Inc., (NYSE: ABBV), the company behind the first-in-class Bruton’s tyrosine kinase (BTK) inhibitor...

Posts pagination

1 … 537 538 539 … 689

Recent updates

  • Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics
  • Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval
  • Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy
  • Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile
  • Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Company Drug

Juventas Cell Therapy’s CAR-T Therapy Yuanruida Receives HSA Filing Acceptance for r/r B-ALL – Expanding Global Regulatory Footprint Following NMPA Approval

Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Company Drug

Beijing Sinotau Secures NMPA Approval for XTR021 Radiodrug Clinical Trial in mCRPC – Next-Generation PSMA-Targeted Therapy Shows Enhanced Efficacy Profile

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.